5 Aug 2020 07:00
5 August 2020
Physiomics plc
("Physiomics" or "the Company")
Issue of Equity and Director Dealing
Physiomics plc, a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, announces that following the receipt of notices of exercise of employee options, 1,655,813 ordinary shares of 0.4p each in the Company ("Ordinary Shares") (the "Options Shares") have now been issued to the following employees at the following exercise prices:
Grantee | Number of Options Shares issued | Exercise price per option |
Dr J Millen, CEO | 1,453,923 | 2.5p |
Other staff | 201,890 | 2.5p |
Application will be made for the Option Shares to be admitted to trading on AIM, and dealings in the Option Shares are expected to commence on 11 August 2020 ("Admission"). Following Admission, the total number of Ordinary Shares in issue will increase to 97,244,778.
For the purposes of the Financial Services Authority's Disclosure Guidance and Transparency Rules (the "DTRs"), the issued ordinary share capital of the Company following Admission will consist of 97,244,778 Ordinary Shares with voting rights attached (one vote per Ordinary Share). There are no Ordinary Shares held in treasury. This total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, Physiomics under the DTRs. The Company's share capital additionally comprises 2,481,657,918 deferred shares of 0.036p each which are not quoted and to which no voting rights attach.
Following Admission, Dr Millen will be interested in 1,984,279 Ordinary Shares, representing approximately 2.04% of the Company's then issued share capital.
The information contained within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No. 596/2014.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Strand Hanson Ltd (NOMAD)
Richard Tulloch & James Dance
+44 (0)20 7409 3494
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name | James Millen | ||||
2 | Reason for the notification | |||||
a) | Position/status | Director, CEO | ||||
b) | Initial notification/ Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Physiomics plc | ||||
b) | LEI | 213800A71DSZ6ABMTQ91 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument
Identification code | Exercise of options over Ordinary share
GB00BDR6W943 | ||||
b) | Nature of the transaction | Exercise of options over Ordinary share | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information - Aggregated volume - Price |
1,453,923 At 2.5p per share | ||||
e) | Date of the transaction | 5 August 2020 | ||||
f) | Place of the transaction | Outside of trading venue | ||||
Physiomics (PYC)